Cargando…
The patient experience of relapsed refractory multiple myeloma and perspectives on emerging therapies
BACKGROUND: Relapsed refractory multiple myeloma (RRMM) is a disease that is nonresponsive or progressive on therapy, and although patients can achieve remission, relapse is common. As more treatment options become available for multiple myeloma (MM), it is important to understand patients' exp...
Autores principales: | Crawford, Rebecca, Gries, Katharine S., Valluri, Satish, Fastenau, John, Morrison, Ross, Yeh, Tzu‐Min, Olyslager, Yunsi, Goldberg, Jenna D., Schecter, Jordan M., Jackson, Carolyn C., Deraedt, William, Doward, Lynda |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9675381/ https://www.ncbi.nlm.nih.gov/pubmed/35168299 http://dx.doi.org/10.1002/cnr2.1603 |
Ejemplares similares
-
Comparative effectiveness of ciltacabtagene autoleucel in CARTITUDE‐1 versus physician's choice of therapy in the Flatiron Health multiple myeloma cohort registry for the treatment of patients with relapsed or refractory multiple myeloma
por: Martin, Thomas, et al.
Publicado: (2021) -
Ciltacabtagene Autoleucel, an Anti–B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up
por: Martin, Thomas, et al.
Publicado: (2023) -
P899: REAL-WORLD ASSESSMENT OF TREATMENT PATTERNS AND OUTCOMES IN PATIENTS WITH LENALIDOMIDE-REFRACTORY RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM THE OPTUM DATABASE
por: Dhakal, B., et al.
Publicado: (2022) -
Using a digital patient powered research network to identify outcomes of importance to patients with multiple myeloma
por: Gries, Katharine S., et al.
Publicado: (2020) -
P35 ANALYSIS OF DARATUMUMAB CLINICAL TRIALS: CHARACTERISTICS AND OUTCOMES IN PATIENTS WITH LENALIDOMIDE-REFRACTORY RELAPSED/REFRACTORY MULTIPLE MYELOMA TREATED WITH 1-3 PRIOR LINES OF THERAPY
por: Einsele, H., et al.
Publicado: (2023)